MedDataX Logo

Special Drug Use-Results Survey of Lipitor Tablets

NCT ID: NCT01446679

Last Updated: 2013-02-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24050 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque

NCT00408382

Hypercholesteremia Coronary Artery Disease
COMPLETED PHASE4

Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

NCT01386853

Hyperlipidemia
UNKNOWN PHASE3

The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

NCT01285544

Dyslipidemia Cardiovascular Disease Hypercholesterolemia
COMPLETED PHASE4

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

NCT01013103

Coronary Artery Disease HMG-CoA Reductase Inhibitor Toxicity Atherosclerosis +2 more
COMPLETED PHASE4

To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients

NCT06866509

Dyslipidemia
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of treatment with Lipitor®(Generic Name : atorvastatin calcium) Tablets and determine the rate of achievement of the category-specific target LDL-C level in patients with hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in patients who have not responded sufficiently to other statin therapies

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

atrovastatin group

Who receive atrovastatin

atrovastatin

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atrovastatin

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with hypercholesterolemia who have not achieved the category-specific target lipid level
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astellas Pharma Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Use Central Contract

Role: STUDY_CHAIR

Astellas Pharma Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chugoku, , Japan

Site Status

Chūbu, , Japan

Site Status

Hokkaido, , Japan

Site Status

Kansai, , Japan

Site Status

Kantou, , Japan

Site Status

Kyushu, , Japan

Site Status

Shikoku, , Japan

Site Status

Tōhoku, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LIP003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
NCT00249249 COMPLETED PHASE3
Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers
NCT02245269 COMPLETED PHASE1
CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
NCT02288338 COMPLETED PHASE1
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
NCT00889226 COMPLETED PHASE4
Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)
NCT00861861 COMPLETED PHASE4
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers
NCT01115985 COMPLETED PHASE1
Drug Interaction Study of ASC42 With Atorvastatin
NCT05464628 COMPLETED PHASE1
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
NCT02550288 COMPLETED PHASE3
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
NCT00452842 TERMINATED
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
NCT00137462 COMPLETED PHASE3
Dyslipidemia in Cardiovascular Disease
NCT01029522 COMPLETED PHASE4
Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease
NCT00293748 COMPLETED
Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"
NCT04325009 UNKNOWN PHASE1
Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin
NCT00973986 COMPLETED PHASE1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
NCT01218204 COMPLETED PHASE2
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670 COMPLETED PHASE4
Bioavailability Study for New Atorvastatin Formulation
NCT00844376 COMPLETED PHASE4
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
NCT05761444 COMPLETED PHASE4
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT00442325 COMPLETED PHASE4
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
NCT01544309 COMPLETED NA
Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin
NCT00722956 COMPLETED PHASE1
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00442845 COMPLETED PHASE4
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
NCT01370590 COMPLETED PHASE3
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
NCT00134485 COMPLETED PHASE3
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
NCT00977288 COMPLETED PHASE2